113558-15-9
113558-15-9 结构式
基本信息
宝藿苷I
宝藿苷Ⅰ
脱水淫羊藿苷)
宝藿苷I对照品,
宝藿苷I(标准品)
宝藿苷I,淫羊藿次苷Ⅱ
宝藿苷Ⅰ(分析标准品)
宝藿苷I, 来源于淫羊藿
宝藿苷I/ 淫羊藿次苷2
Icariin II
Icarisid II
Baohuside I
BaohuosideⅠ
Baohuoside-1
baohuoside I
Icariside II 113558-15-9
Baohuoside I(Icariside II)
Baohuoside I Baohuside I
物理化学性质
制备方法
489-32-7
113558-15-9
以淫羊藿苷为原料合成5,7-二羟基-2-(4-甲氧基苯基)-8-(3-甲基-2-丁烯-1-基)-3-(((2S,3R,4R,5R,6S)-3,4,5-三羟基-6-甲基四氢-2H-吡喃-2-基)氧基)-4H-苯并吡喃-4-酮的一般步骤如下：首先，将来自琼脂斜面（2 cm2）的C. blakesleeana菌丝体转移至100 mL培养基中，于30℃、175 rpm条件下培养36小时，制备接种物。随后，将10 mL接种物加入至1000 mL液体培养基中，并将烧瓶置于旋转振荡器上，在175 rpm、30℃条件下预培养36小时。预培养完成后，将100 mg淫羊藿苷溶于2 mL甲醇中，加入至2 L培养基中进行制备性生物转化，使终浓度达到50 mg/L。继续培养5天后，过滤培养物，用等体积的EtOAc对滤液进行五次萃取。同时，使用1000 mL EtOAc对C. blakesleeana的悬浮细胞（5.2 g）进行提取。合并所有EtOAc萃取物，减压浓缩。将所得残余物（1.6 g）上样至ODS柱（200 g，10 cm × 50 cm），以MeOH-H?O（10%至90%梯度，流速2.0 mL/min）进行洗脱。最终，从60% MeOH洗脱的级分（500 mL）中获得90.1 mg icariside II，纯度为96.5%。
参考文献：
[1] Journal of Molecular Catalysis B: Enzymatic, 2015, vol. 122, p. 141 - 146
[2] Patent: CN104530127, 2016, B. Location in patent: Paragraph 0156-0159
[3] Patent: CN104387430, 2017, B. Location in patent: Paragraph 0109; 0110; 0111; 0112
[4] Journal of Natural Products, 2008, vol. 71, # 9, p. 1513 - 1517
[5] Journal of Asian Natural Products Research, 2015, vol. 17, # 6, p. 656 - 661
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-N0011 | 宝藿苷I Baohuoside I | 113558-15-9 | 5 mg | 800元 |
| 2025/05/22 | HY-N0011 | 宝藿苷I Baohuoside I | 113558-15-9 | 10mg | 1200元 |
| 2025/05/22 | HY-N0011 | 宝藿苷I Baohuoside I | 113558-15-9 | 10mM * 1mLin DMSO | 1320元 |
常见问题列表
|
CXCR4
|
Baohuoside I is an inhibitor of CXCR4, and downregulates CXCR4 expression at 12-25 μM. Baohuoside I (0-25 μM) suppresses NF-κB activation in a dose-dependent manner, suppresses CXCL12 induced the invasion of cervical cancer cells. Baohuoside I also inhibits invasion of breast cancer cells. Baohuoside I inhibits A549 cell viability, with IC 50 s of 25.1 μM at 24 h, 11.5 μM and 9.6 μM at 48 h and 72 h, respectively. Baohuoside I ((25 μM) suppresses the caspase cascade in A549 cells, elevates ROS levels and activates JNK and p38 MAPK signaling cascade. Baohuoside I (3.125, 6.25, 12.5, 25.0 and 50.0 µg/mL) significantly and dose-dependently blocks the growth of esophageal squamous cell carcinoma Eca109 cells, with an IC 50 of 4.8 µg/mL at 48 h.
Baohuoside I (25 mg/kg) decreases β-catenin protein levels, cyclin D1 and survivin expression in nude mice.